Treatment for small cell lung cancer, where are we now?-a review.

Abstract

Small cell lung cancer (SCLC) represents between 13% and 15% of all diagnosed lung cancers worldwide. It is an aggressive neoplasia, with a 5-year mortality of 90% or more. It has historically been classified as limited disease (LD) and extensive disease (ED) in most study protocols. The cornerstone of treatment for any stage of SCLC is etoposide-platinum… (More)
DOI: 10.3978/j.issn.2218-6751.2016.01.13

Topics

Cite this paper

@article{AlvaradoLuna2016TreatmentFS, title={Treatment for small cell lung cancer, where are we now?-a review.}, author={Gabriela Alvarado-Luna and Daniela Morales-Espinosa}, journal={Translational lung cancer research}, year={2016}, volume={5 1}, pages={26-38} }